What a day and what a result.
I haven't been through all the posts today, but one thing I think we should consider is the data monitoring committee may end the NIH trial early. Given the response rate seen in the first 12 patients there is absolutely no reason to do a 240 patient trial to get a clinically significant result and it would arguably be unethical to continue the trial if they already have more than 50 patients treated. Things could move much faster than many people are thinking.
Given then FDA has all the safety and manufacturing data it needs, approval could be very, very fast. Hold on guys.
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-313
-
- There are more pages in this discussion • 535 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
0.020(1.34%) |
Mkt cap ! $1.724B | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.58 | $1.41 | $18.15M | 12.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3418 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 24361 | 5 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |